NCT07544680Active, not recruiting
Endometrial Cancer Vaginal Fluid Specimen Collection Study
Endometrial Cancer Vaginal Fluid Specimen Collection Study: "ENVISION"
Source: ClinicalTrials.gov · Last updated 5 Oct 2026
Brief summary (registry, in English)
This is a multicenter, prospective, specimen collection study for development and evaluation of tests used to detect endometrial cancer, other cancers, or their causes.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 4200 (estimated)
- First submitted
- 31 Mar 2026
- Start date
- 10 Mar 2026
- Primary completion date
- 24 Apr 2028
- Lead sponsor
- Exact Sciences Corporation
- Diseases
- Endometrial cancer
- NCT number
- NCT07544680
What you commit to
- Study type: Observational
- Planned participants: 4200
- From 10 Mar 2026 to the primary completion date, 24 Apr 2028
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior partial or complete hysterectomy
- Prior pelvic or vaginal radiotherapy
- Chemotherapy within past 5 years (except tamoxifen)
- Prior cervical cancer or biopsy-proven cervical dysplasia
- Surgery for recurrent EC
- Preoperative neoadjuvant chemotherapy or radiotherapy for current EC
- Prior treatment or surgery to remove target pathology during current episode
Other illness
- Any condition judged by the Investigator to preclude participation
- Additional for Cohort 1:
- Cancer diagnosis within past 5 years (except non-gynecologic skin cancer)
- Current biopsy-proven cervical, vaginal, or vulvar cancer, or lower genital tract dysplasia
- Current biopsy-proven endometrial cancer, hyperplasia, or benign polyp
- Cancer diagnosis other than EC within past 5 years (except non-gynecologic skin cancer)
Other
- Current pregnancy
- Benign endometrial biopsy within last month
- Additional for Cohort 2:
Who the study is looking for
- Cohort 1 Participants:
- Age ≥ 45 years, OR age ≥ 18 years with at least one risk factor
- Diagnosed with abnormal uterine bleeding (AUB)
- Planning standard-of-care endometrial tissue sampling to assess for endometrial cancer (EC) or atypical endometrial hyperplasia/endometrial intraepithelial neoplasia (AEH/EIN)
- Cohort 2 Participants:
- Age ≥ 18 years
- Newly diagnosed, biopsy-confirmed EC or AEH/EIN
- Planning initial management for their endometrial pathology
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Research Center - Frisco Coordinator of this site? Confirm its status | Frisco | United States | Unknown status |
| Murfreesboro Medical Clinic Coordinator of this site? Confirm its status | Murfreesboro | United States | Unknown status |
| IC Research Coordinator of this site? Confirm its status | Murfreesboro | United States | Unknown status |
| Physical Care Clinical Research Coordinator of this site? Confirm its status | Sarasota | United States | Unknown status |
| MaineHealth Coordinator of this site? Confirm its status | Scarborough | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.